Worldwide, approximately 2.5 million children are infected with HIV, and approximately 1,700 new perinatal infections occur daily, according to background information in the article. In the United States, more than 9,300 HIV-infected children younger than 13 years have progressed to AIDS as of December 2003. While the Pediatric AIDS Clinical Trials Group (PACTG) 076 regimen has reduced perinatal transmission by 67 percent, prenatal combination ART has further reduced transmission to 2 percent or less. However, the impact of treatment on progression of perinatal HIV infection remains poorly characterized at the population level. Perinatal HIV infection may progress in 2 patterns: early, with a typical onset of age 4 months, or late, with a typical onset of age 6 years.
David R. Berk, M.D., of the Stanford University School of Medicine, Stanford, Calif., and colleagues conducted a study to determine the progression of HIV, survival, and distribution of category C (the most severe of three categories, dependent on symptomatic conditions) diagnoses in a perinatal population-based sample during different eras in prevention and management and in relation to early institution of any ART therapy. The researchers examined the trends in early progression of perinatal HIV infection among 205 HIV-infected children in Northern California born between January 1, 1988, and December 31, 2001, and followed up through age 3 years.
The researchers found that of 205 children, 134 (65 percent) received ART and/or prophylactic treatment against Pneumocystis jiroveci pneumonia. By age 3 years, 81 (40 percent) progressed to a category C diagnosis, 41 (51 percent) of whom died. Untreated children were significantly more likely to progress to a category C diagnosis (62 percent [44/71] untreated vs. 28 pe
Contact: Krista Conger
JAMA and Archives Journals